Existing investor Takeda Ventures was among the participants in a round that valued the cancer therapy developer at approximately $100m.
US-based oncology therapy startup VelosBio has raised $58m in series A funding from investors including Takeda Ventures and Chiesi Ventures, subsidiaries of pharmaceutical companies Takeda and Chiesi.
Healthcare company builder Arix Bioscience co-led the round with Sofinnova Ventures, paying $11m for an 11.2% stake in the company. Pappas Ventures and Decheng Capital also took part, and Arix investment director Mark Chin will join the board of directors at VelosBio.
Founded in 2017, VelosBio is working on antibody-drug conjugates that will…
